NFJ Investment Group LLC Has $5.80 Million Stock Holdings in IQVIA Holdings Inc. $IQV

Key Points

• NFJ Investment Group LLC reduced its stake in IQVIA Holdings Inc. by 10.8%, owning 32,902 shares worth approximately $5.8 million after selling 3,991 shares in the first quarter.
• Several institutional investors have increased their positions in IQVIA, with Mather Group LLC increasing its stake by 83.5% and Park Avenue Securities LLC by 40.4% during the same period.
• IQVIA reported quarterly earnings beating estimates with $2.81 EPS and a revenue of $4.02 billion, surpassing analyst expectations of $3.96 billion.

NFJ Investment Group LLC lowered its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 10.8% in the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 32,902 shares of the medical research company's stock after selling 3,991 shares during the period. NFJ Investment Group LLC's holdings in IQVIA were worth $5,801,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. American National Bank & Trust bought a new stake in shares of IQVIA in the 1st quarter valued at approximately $26,000. Clal Insurance Enterprises Holdings Ltd lifted its position in shares of IQVIA by 436.7% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company's stock worth $28,000 after buying an additional 131 shares during the last quarter. Golden State Wealth Management LLC boosted its holdings in shares of IQVIA by 295.5% in the 1st quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock valued at $31,000 after buying an additional 130 shares during the period. AllSquare Wealth Management LLC acquired a new stake in IQVIA during the first quarter worth about $33,000. Finally, ST Germain D J Co. Inc. lifted its holdings in IQVIA by 66.1% in the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after acquiring an additional 76 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

Insider Transactions at IQVIA

In other news, insider Keriann Cherofsky sold 549 shares of the firm's stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the sale, the insider owned 2,910 shares of the company's stock, valued at $557,352.30. This trade represents a 15.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Eric Sherbet sold 5,800 shares of the company's stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the transaction, the insider directly owned 27,178 shares in the company, valued at $5,165,178.90. The trade was a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by corporate insiders.

IQVIA Price Performance

Shares of IQV traded up $2.21 during mid-day trading on Tuesday, hitting $189.89. The company's stock had a trading volume of 1,200,874 shares, compared to its average volume of 1,160,792. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84. The firm has a 50-day moving average price of $181.03 and a 200 day moving average price of $167.36. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $248.03. The stock has a market capitalization of $32.28 billion, a price-to-earnings ratio of 27.48, a PEG ratio of 2.06 and a beta of 1.32.

IQVIA (NYSE:IQV - Get Free Report) last issued its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, topping analysts' consensus estimates of $2.77 by $0.04. The firm had revenue of $4.02 billion during the quarter, compared to analysts' expectations of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The firm's revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period last year, the firm posted $2.64 earnings per share. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, research analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on IQV. Robert W. Baird boosted their price objective on IQVIA from $159.00 to $196.00 and gave the company a "neutral" rating in a research report on Wednesday, July 23rd. Cowen reaffirmed a "buy" rating on shares of IQVIA in a report on Wednesday, July 23rd. Redburn Partners set a $214.00 target price on shares of IQVIA in a research note on Wednesday, September 3rd. Barclays raised their price target on shares of IQVIA from $165.00 to $185.00 and gave the company an "equal weight" rating in a research note on Wednesday, July 23rd. Finally, Mizuho lifted their target price on IQVIA from $190.00 to $225.00 and gave the company an "outperform" rating in a research note on Friday, July 25th. Eighteen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $229.64.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.